dulaglutide

GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

Home
Ligands
dulaglutide

GtoPdb Ligand ID: 7638

Synonyms: GLP-1Fc | LY2189265 | Trulicity®

dulaglutide is an approved drug (EMA & FDA (2014))

Compound class: Peptide

Comment: Dulaglutide is a GLP-1 mimetic. This treatment has the benefit of being long-acting, with in vivo studies showing peptide immunoreactivity is detactable >6 days following administration [2]. Therefore dulaglutide requires administration only once a week [1].

References
1. Arslanian SA, Hannon T, Zeitler P, Chao LC, Boucher-Berry C, Barrientos-Pérez M, Bismuth E, Dib S, Cho JI, Cox D et al.. (2022) Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes. N Engl J Med, 387 (5): 433-443. [PMID:35658022]
2. Glaesner W, Vick AM, Millican R, Ellis B, Tschang SH, Tian Y, Bokvist K, Brenner M, Koester A, Porksen N et al.. (2010) Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein. Diabetes Metab Res Rev, 26 (4): 287-96. [PMID:20503261]

References

1. Arslanian SA, Hannon T, Zeitler P, Chao LC, Boucher-Berry C, Barrientos-Pérez M, Bismuth E, Dib S, Cho JI, Cox D et al.. (2022)
Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes.
N Engl J Med, 387 (5): 433-443. [PMID:35658022]

2. Glaesner W, Vick AM, Millican R, Ellis B, Tschang SH, Tian Y, Bokvist K, Brenner M, Koester A, Porksen N et al.. (2010)
Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein.
Diabetes Metab Res Rev, 26 (4): 287-96. [PMID:20503261]